EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach

Lenci K Vázquez-Jiménez iD, Alonzo González-González, Timoteo Delgado-Maldonado iD, Rogelio Gómez-Escobedo, Guadalupe Avalos-Navarro iD, Adriana Moreno-Rodríguez iD, Alma D Paz-González, Eyra Ortiz-Pérez iD, Benjamín Nogueda-Torres, Gildardo Rivera iD

Molecules · 17.04.2026 · 31 (8) · 1327

DOI: 10.3390/molecules31081327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 17.04.2026. Verfasst von Lenci K Vázquez-Jiménez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Trypanocidal Agents, Drug Repositioning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional, Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease affects millions of people worldwide, including those in Latin America. The only drugs available for its treatment are benznidazole and nifurtimox. However, these drugs present high toxicity and limited efficacy. Therefore, the search for new treatments continues. In this regard, computer-assisted drug design has been implemented in scientific research for drug repurposing, allowing for reduced costs and time. Therefore, the objective of this work was to search for analogs of FDA-approved drugs with activity against Trypanosoma cruzi through ligand-based virtual screening and their biological evaluation against blood trypomastigotes. The compound TD-095 (LC50 = 48.60 and 13.75 µM), a ketanserin analogue, TS-936 (LC50 = 71.55 and 37.54 µM), a terfenadine analogue, and TD-831 (LC50 = 75.94 and 26.17 µM), a sulfasalazine analogue, were considered as potential trans-sialidase inhibitors; TIM-967 (LC50 = 69.70 and 39.69 µM) and LK-284 (LC50 = 116.7 and 82.29 µM), two sulfonylurea analogues, were considered as potential triosephosphate isomerase inhibitors, showing better trypanocidal activity against NINOA and INC-5 strains, respectively, than the reference drugs. Molecular dynamics simulations predicted the stability of the compounds in complex with their respective proteins. Finally, the ADMET predictive analysis showed favorable properties for the compounds. These results support continued research into new agents against Trypanosoma cruzi, using structures of drugs already approved by the FDA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma cruziTrypanocidal AgentsDrug RepositioningChagas DiseaseHumansMolecular Docking SimulationMolecular Dynamics SimulationTriose-Phosphate IsomeraseGlycoproteinsNeuraminidase

Stichwörter der Autor:innen

FDA drugsTrans-sialidaseTrypanosoma cruzidrug repositioningmolecular dockingtriosephosphate isomerase

Substanzen

Trypanocidal AgentsTriose-Phosphate Isomerasetrans-sialidaseGlycoproteinsNeuraminidase

Autor:innen und Institutionen

  • Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
  • Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), Ciudad de México 03940, Mexico.
  • Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  • Departamento de Ciencias Médicas y de la Vida, Centro Universitario de la Ciénega (CUCIÉNEGA), Universidad de Guadalajara, Av. Universidad 1115, Lindavista, Ocotlán 47820, Mexico.
  • Laboratorio de Estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de Ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Avenida Universidad S/N, Ex Hacienda Cinco Señore…

ORCID-Profile: Lenci K Vázquez-Jiménez, Timoteo Delgado-Maldonado, Guadalupe Avalos-Navarro, Adriana Moreno-Rodríguez, Eyra Ortiz-Pérez, Gildardo Rivera

Förderung

  • Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional
  • Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional

Zitieren

APA

Vázquez-Jiménez, L. K., González-González, A., Delgado-Maldonado, T., Gómez-Escobedo, R., Avalos-Navarro, G., Moreno-Rodríguez, A., Paz-González, A. D., Ortiz-Pérez, E., Nogueda-Torres, B., & Rivera, G. (2026). Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach. Molecules, 31(8), 1327. https://doi.org/10.3390/molecules31081327

Vancouver

Vázquez-Jiménez LK, González-González A, Delgado-Maldonado T, Gómez-Escobedo R, Avalos-Navarro G, Moreno-Rodríguez A, et al. Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach. Molecules. 2026;31(8):1327. doi:10.3390/molecules31081327

BibTeX
@article{VzquezJimnez2026,
  author = {Vázquez-Jiménez, Lenci K and González-González, Alonzo and Delgado-Maldonado, Timoteo and Gómez-Escobedo, Rogelio and Avalos-Navarro, Guadalupe and Moreno-Rodríguez, Adriana and Paz-González, Alma D and Ortiz-Pérez, Eyra and Nogueda-Torres, Benjamín and Rivera, Gildardo},
  title = {Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {8},
  pages = {1327},
  doi = {10.3390/molecules31081327}
}
Kostenlos starten →